

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- ✓ • BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

REMARKS

Applicants submit the enclosed substitute specification to replace the specification filed on January 7, 2002, because the originally filed specification inadvertently omitted Tables 1-5. Tables 1-5 were included in the specification of Provisional Application 60/152,011, filed September 1, 1999, and the specification of Utility Application 09/653,030, filed September 1, 2000, to which the present application claims priority. Therefore, submission of the substitute specification, including Tables 1-5 provided on pages 14, 17, 24, 26, and 28, does not introduce new matter.


CONCLUSION

Applicants submit that, following entry of the substitute specification, all of the requirements for allowance of this application have been met. Accordingly, Applicants respectfully request notification to that effect and issuance of a Notice of Allowance.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: Dec. 15, 2003



Paul T. Clark
Reg. No. 30,162

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



Version With Markings Showing Changes Made

PATENT
ATTORNEY DOCKET NO: 50047/006003

METHOD OF ASSAYING MODULATORS OF HYPERTENSION

Cross Reference to Related Applications

5 This application is a continuation application and claims priority from
Utility Application 09/653,030, filed September 1, 2000, now abandoned, which
claims priority from Provisional Application 60/152,011, filed September 1, 1999.

Statement as to Federally Sponsored Research

10 The invention was made with funding from the National Institutes of
Health, grants HL 58136 and HL 48903. The government may have certain rights
in the invention.

FIELD OF THE INVENTION

The invention relates to methods useful for delaying or ameliorating
diseases associated with hypertension.

15 BACKGROUND OF THE INVENTION

Essential hypertension (EHT; 1) is a paradigmatic, complex, and
multifactorial condition. Genes that mediate EHT have therefore been difficult to
isolate and characterize, requiring multiple lines of evidence to establish their roles
in EHT pathogenesis.

20 In view of the wide range of disorders that are associated with
hypertension, it would be desirable to identify compounds for the treatment or
prevention of hypertension.

SUMMARY OF THE INVENTION

Here we present evidence of the identification and characterization of an EHT susceptibility gene. The invention provides methods for identifying compounds which affect hypertension.

5 In one aspect, the invention features a method of assaying a test compound, by providing a non-human mammal with a functionally variant hypertension susceptibility gene, administering said test compound to said non-human mammal, and determining whether the test compound affects hypertension parameters in the non-human mammal relative to a non-human mammal
10 containing a wild type hypertension susceptibility gene.

 In preferred embodiments of the invention, the hypertension susceptibility gene is the $\alpha 1$ Na,K ATPase gene and the non-human mammal is a rat, preferably the Dahl S rat.

 By "test compound" is meant any chemical compound, be it naturally-
15 occurring or artificially-derived. Test compounds may include, for example, peptides, polypeptides, synthesized organic molecules, naturally occurring organic molecules, and nucleic acid molecules.

 By "affects" is meant changes, either by increase or decrease.

 By "determining" is meant analyzing the effect of a test compound on
20 the test system. The readout of the analysis may be measurement of life span, blood pressure, renal pathology, and other hypertension parameters known to those skilled in the art.

 The invention provides a means for assaying compounds that affect hypertension by means of an animal model in which a hypertension susceptibility
25 gene has been identified. Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1A-1B show the genetic analysis of Dahl S^{HSD} rats.

Fig. 2A-2G show molecular characteristics of transgenic Tg[wta1] lines.

5 Fig. 3A-3B show life span in hemizygous and homozygous transgenic Tg[wta1] Dahl S rats compared with control non-transgenic Dahl S rats.

Fig. 4A-4G show the comparative analysis of degree of hypertensive renal disease.

10 Fig. 5 shows the cosegregation analysis of $\alpha 1$ Na,K-ATPase locus with salt-sensitive hypertension.

DETAILED DESCRIPTION OF THE INVENTION

Given the difficulty of isolation and characterization of genes mediating EHT, delineation of a putative EHT susceptibility gene should meet the following
15 criteria: 1, identification of a functionally significant structural mutation in the relevant gene; 2, concordance of the observed genetic dysfunction with a pathophysiologic mechanism logical to the hypertension pathogenesis; 3, association of the putative hypertension susceptibility gene with hypertension in validated genetic animal models or human hypertensive patients; and 4,
20 delineation of the mechanistic role in an *in vivo* model (1, 2). To date, no EHT susceptibility gene has been identified that meets all these criteria.

To simplify the molecular genetic characterization of an EHT susceptibility gene, one subtype of EHT, salt-sensitive hypertension (SS-EHT), was studied. The hypothesis that variants of the $\alpha 1$ Na,K-ATPase gene mediate
25 SS-EHT in a genetic rat model of hypertension, was tested using the Dahl S

hypertensive rat strain (3, 4). Because $\alpha 1$ Na,K-ATPase is the sole active Na⁺ transporter in the renal basolateral epithelia throughout the nephron (5, 6), it is a logical candidate gene to be considered in the assessment of the abnormal renal sodium handling in the Dahl S rat (7).

5 Two of the four criteria stated above (1, 2) and required to define the $\alpha 1$ Na,K-ATPase gene as an EHT susceptibility gene have been met. For criterion 1, a Q276L substitution in the $\alpha 1$ Na,K-ATPase gene in inbred Dahl S rats from Harlan Sprague Dawley, Inc. (Indianapolis, IN) (Dahl SHSD) has been characterized (8, 9). In contrast to the non-detection by PCR sequencing reported
10 by Simonet et al. (10), the Q276L $\alpha 1$ Na,K-ATPase variant was confirmed in Dahl S genomic DNA by using PCR error-independent assays (polymerase allele specific amplification, PASA, and 3' mismatch correction assay) and ligase chain reaction assay; in kidney RNA by RTth-PCR; and in cDNA clones by resequencing (9). Likewise, detection of the wild-type (wt) Q276 sequence (11)
15 was confirmed in Dahl R genomic DNA and in resequenced cDNA clones (9).

 The Q276L mutation results in decreased K⁺ (⁸⁶Rb⁺) influx detected in *Xenopus* oocyte expression experiments using both Dahl S kidney polyA⁺ RNA, as well as *in vitro* transcribed variant Q276L-specific cRNA transcript, in contrast to control Dahl R rat kidney polyA⁺ RNA and *in vitro* transcribed wt Q276 cRNA
20 transcript, respectively (8). Kinetic studies of $\alpha 1$ Na,K-ATPases in red blood cell flux experiments, comparing Dahl S and Dahl R $\alpha 1$ Na,K-ATPases corroborated decreased K⁺ (⁸⁶Rb⁺) influx and revealed normal Na⁺ transport resulting in an increased Na:K coupling ratio in the Dahl S Q276L $\alpha 1$ Na,K-ATPase variant (12). For criterion 2, simulated modeling studies have revealed that consequences of
25 an increased Na:K coupling ratio (from 3:2 to 3:1) observed in the Q276L $\alpha 1$ Na,K-ATPase variant results in an altered set point for cellular Na⁺ metabolism,

with higher sodium reabsorption at unchanged Na,K-ATPase levels in the proximal convoluted tubule, as well as in the thick ascending limb of the loop of Henle (13), thus providing a mechanistic hypothesis for increased Na⁺ reabsorption in Dahl S rats.

5 To fulfill criteria 3 and 4, the following questions were addressed: does the Q276L α 1 Na,K-ATPase variant contribute to the salt-sensitive hypertension phenotype? and does the functionally aberrant Q276L α 1 Na,K-ATPase allele cosegregate with salt-sensitive hypertension? These questions were addressed using transgenic experiments and a standard intercross linkage analysis strategy.

10 Because of the inadvertent genetic contamination of the Dahl S^{HSD} strain (19, 24), transgenic studies were performed using only Dahl S^{HSD} rats from the foundation colonies at Harlan Sprague, Inc. confirmed as to genotype and salt-sensitive phenotype (19). The F2 intercross was also done using Dahl S^{HSD} and Dahl R^{HSD} rats confirmed for both genotype and phenotype. Unequivocal
15 observations are thus ascertained (19).

 The results obtained from the transgenic and cosegregation studies fulfill the requirements of the criteria set out to definitively assign the α 1 Na,K-ATPase gene as a susceptibility gene for hypertension using the Dahl S^{HSD} genetic hypertension rat model. The concordance of improvement not just in all
20 measures of blood pressure, but also in renal disease and life span, provides holistic support strengthening the ascertainment of the mechanistic role of α 1 Na,K-ATPase in salt-sensitive hypertension as modeled in the Dahl S^{HSD} rat. The results indicate that phenotypic differences observed in the transgenic Tg[wt α 1] rats are most likely due to the functional heterozygosity of wt and Q276L variant
25 α 1 Na,K-ATPases rather than an additive overabundance of α 1 Na,K-ATPases. This is consistent with the observation made from blood pressure data of F1(S \times R)

rats, indicating that hypertension is a recessive trait and that normotension is a dominant trait.

Other genetic studies have documented previous linkage of the $\alpha 1$ Na,K-ATPase locus. The $\alpha 1$ Na,K-ATPase locus was found to be the closest
5 candidate gene in a total chromosome 2 scan analyzing two F2 cohorts, one involving the Dahl S×Milan normotensive strain, and one involving Dahl S×Wistar Kyoto normotensive strain (22). Recent studies on chromosome 2 analyzing F2 crosses derived from the stroke-prone spontaneously hypertensive rat and the normotensive Wistar-Kyoto rat (25) and derived from the spontaneously
10 hypertensive rat and the Wistar-Kyoto rat (26) have also detected a QTL for high blood pressure close to the $\alpha 1$ Na,K-ATPase locus. The cosegregation study presented herein independently confirms these previous results and with $P < 0.003$, meets the required nominal $P < 0.01$ criterion for confirmed linkage (27).

The pronounced improvement in blood pressure ($\sim 40\%$) by the
15 transgenic manipulation of a single gene suggests that hypertension, being polygenic, does not, most likely, follow a simple additive model of genetic inheritance, but rather involves a di- or multigenic interaction within a polygenic context. With normotension being dominant, transgenic experiments designed to correct hypertension in the inbred hypertensive strain would be more robust in
20 investigating the effects of interacting hypertension susceptibility genes rather than F2 intercross studies with polymorphic markers as shown herein.

The improvement of multiple pathogenic events in transgenic Tg[wta1] Dahl S rats is consistent with observations in human hypertensive patients, wherein lowering of blood pressure has been shown to decrease mortality and
25 target organ complications (28). The greater reduction in the degree of renal pathology (50%) and greater improvement in life span (75.6%) compared with

blood pressure parameters (~ 40%) seen in the transgenic rats could be attributed to an "early" intervention, as the transgenic rats have the corrective transgene from one-cell embryo stage — a finding which promotes the value of early preventive interventions for some complex diseases. Additionally, the $\alpha 1$ Na,K-ATPase gene might play a role in hypertensive renal complication pathogenesis that is distinct from its role in hypertension pathogenesis, and/or a threshold phenomenon might be involved in the pathogenesis of hypertensive target organ complications.

The inability to detect the A¹⁰⁷⁹-T¹⁰⁷⁹ transversion in Dahl S rat genomic DNA via amplification-based methods and sequencing of genomic clones underscores the importance of a multifaceted analysis of such refractory mutations encompassing structural and functional approaches. The demonstration, therefore, of functionally significant differences between Dahl S and Dahl R $\alpha 1$ Na,K-ATPases and, more significantly, the partial correction of salt-sensitive hypertension in the Dahl S rat via transgenesis support the contention that the Q276L mutation exists in Dahl S rats as shown by error-independent assays and that it plays a role in salt-sensitive hypertension. The observation of an amplification error-prone genomic DNA region raises the question that other mutations might be similarly refractory to detection by conventional amplification-based methods. Amplification-independent assays provide an alternative and suitable approach to structurally assess these "refractory" mutations.

Altogether, the results presented herein demonstrate that the Na,K-ATPase locus is a SS-EHT susceptibility gene and showcases the strength of a "forward genetics approach" testing functionally significant variant alleles at biologically relevant loci (1, 29) -- as was done recently in the study of the variant serotonin transporter as a gene contributing to neuroticism (30). It also indicates

the value of a multifaceted molecular genetic approach (1, 31), wherein transgenic rat experiments in an inbred model organism might allow one to deduce the role of a gene in complex disease pathogenesis. The success in the significant alleviation of salt-sensitive hypertension by the manipulation of a single gene validates the potential for gene therapy for complex cardiovascular diseases and other multifactorial disorders. Moreover, the proposed criteria and approach in animal models provide evidence that make analogous studies of homologous human genes in hypertension compelling.

The following examples are to illustrate the invention. They are not meant to limit the invention in any way.

EXAMPLE 1

METHODS

Genotype and PASA analysis of Dahl S and Dahl R rats.

Foundation colony Dahl S and Dahl R rats were obtained from Harlan Sprague Dawley Inc. derived from breeding pairs procured from J. Rapp (Medical College of Ohio, Toledo, OH) in 1985. Newly obtained Dahl S^{Rapp} rats from J. Rapp were obtained by and analyzed by Harlan Sprague Dawley, Inc. (Indianapolis, IN) for comparative analysis. All marker rat map pairs were obtained from Research Genetics (Huntsville, AL). Genotyping conditions were optimized and done as described (9, 14). For PASA analysis, rat spleen genomic DNA was isolated and PASA was done using primer pairs and conditions essentially as described (9) with the following modifications: the optimal stringent PCR cycling conditions were as follows: 95°C×10 min; 30 cycles of (95°C×1 min, 57°C×1 min, 72°C×1 min); extension at 72°C×7 min with 0.5 U/10 µL of AmpliTaq Gold™ (Perkin Elmer Corp., Norwalk, CT).

Development of Dahl S transgenic rats.

The transgene was constructed linking the wt $\alpha 1$ Na,K-ATPase (1288)5' flanking region tested for functionality in tissue culture cells (15), full length 5' UT, full length 1028-amino acid-coding region, 131 bp of 3' UT of the wt $\alpha 1$ Na,K-ATPase cDNA, and 199 bp of SV40 polyadenylation signal sequences. Linearization with PvuI and HindIII restriction enzymes released the intact Tg[wta1] minigene with 233 bp of vector sequence 5' to the minigene, and 237 bp of vector sequence 3' to the minigene, resulting in a total of 5,376 bp. Transgenic rats were developed as described (16) and three founders (Tg₂₄, Tg₃₇, and Tg₄₈) were identified by Southern blot analysis. Only two lines were bred to homozygosity: Tg[wta1]₂₄ and Tg[wta1]₄₈.

Ribonuclease protection assays (RPAs).

RPA was performed with the RPA IITM ribonuclease protection assay kit (Ambion, Austin, TX) as per manufacturer's instructions. The riboprobe was designed to span 131 bp of 3' untranslated region of the rat $\alpha 1$ Na,K-ATPase and 109 bp of SV40 sequence distinguishing the transgene transcript as a 240-nucleotide (nt) protected fragment in contrast to the 131-nt protected fragment of endogenous $\alpha 1$ Na,K-ATPase transcript. 20 μ g of total cellular RNA purified by the guanidinium-CsCl method was used for each assay.

Isolation of rat kidney rough microsomes.

Membrane-bound polysomes were isolated as described (17) using a cation (CsCl)-containing sucrose gradient. The pelleted rough microsomes were dissolved in 10 mM Tris-HCL, pH 7.4, 1 mM EDTA, and the total rough microsomal RNA was isolated by sequential phenol:chloroform (50:50) extraction

followed by ethanol precipitation. 20 µg of rat kidney membrane-bound polysomal RNA was used for RPA using the same riboprobe and experimental conditions described above.

Assessment of life span.

- 5 Life span was assessed in both hemizygous and homozygous transgenic rats. Hemizygous male and female transgenic rats from three lines, along with littermate non-transgenic controls were started on a high salt (8% NaCl) diet at 6 wk of age and observed until natural death. Homozygous male and female rats from two transgenic lines, lines 24 and 48, were compared to non-transgenic
10 Dahl S controls while fed a normal rat chow diet (0.4% NaCl), and observed until natural death. Statistical analysis was done by one-way ANOVA.

Measurement of blood pressure by radiotelemetry.

- Blood pressure was measured using intra-aortic abdominal radiotelemetric implants (DATASCIENCE, St. Paul, MN) obtaining non-stressed
15 blood pressure measurements taking the average over 10 s every 5 min for 24 h (16). The 24-h average of all data points (288) over one no-entry day at said time point after high salt challenge was used for all blood pressure measurements analyzed. The 24-h average was determined to be the best because it would account for diurnal variation, thus ascertaining accuracy. Because telemetric
20 blood pressure signals were collected via computer, measurements were obtained without disturbance from room change, or room entry. Systolic (SBP), diastolic (DBP), and mean arterial pressures (MAP) were measured along with heart rate and activity. The protocol for transgenic and age-matched non-transgenic Dahl S rats was as follows: implant surgery at 10 wk of age; only rats with no

complications after operation were used; after 12 d, baseline blood pressure levels were obtained; high salt (8% NaCl) challenge was begun at 12 wk of age and maintained for 4 wk; and transgenic and control rats were killed after 4 wk on high (8% NaCl) salt challenge (16 wk of age). The protocol for characterization of parental Dahl S and Dahl R rats, F1(S×R) and F2(S×R) hybrid rats was as follows: implant surgery at 8 wk of age; only rats with no complications after operation were used; after 12 d, baseline blood pressures were obtained; and high (8% NaCl) salt challenge was begun at 10 wk of age with water *ad libitum*. After 8 wk of high (8% NaCl) salt challenge, 24-h average SBP, DBP, MAP, and increment rise in 24-h average of SBP, DBP, and MAP were obtained per rat over one no-entry day (288 data points, 10-s recordings every 5 min).

Assessment of renal pathology.

Renal tissues were fixed in 4% buffered paraformaldehyde and processed at HistoTechniques (Ohio). Serial renal sections were stained using hematoxylin-eosin, periodic acid Schiff (PAS), and Masson Trichrome stain. All glomeruli in one renal section (5 µm) were analyzed for degree of glomerulosclerosis and mesangial matrix expansion. Age-matched control non-transgenic and transgenic male and female rats were studied after 4 wk of high salt diet challenge. Glomerulosclerosis was defined as disappearance of cellular elements from the tuft, collapse of capillary lumen, and folding of the glomerular basement membrane with entrapment of amorphous material (18). Mesangial matrix expansion was defined by the presence of increased amounts of PAS-positive material in the mesangial region (18). Renal pathology grade I, 25% of glomerulus with pathology; II, 50% involvement; III, 75% involvement; IV, 100% involvement. The extent of injury for each renal section was calculated, as

the total pathology score = (1 ×% grade I) + (2 ×% grade II) + (3 ×% grade III) + (4 ×% grade IV), increasing with worse injury represented by glomerulosclerosis and mesangial matrix expansion (18). Renal sections were scored in a blind manner. Data were analyzed using non-parametric ANOVA.

5 Cosegregation analysis.

The F2 cohort was derived from one Dahl S male and six Dahl R female rats from HSD colonies previously verified for genotype and phenotype (19).

Non-stressed 24-h average blood pressure measurements were obtained by radiotelemetry, as described above. After 8 wk of high salt challenge, the F2

10 hybrid rats were killed and tail genomic DNAs isolated as described (16).

Genotyping was performed using the following microsatellite markers: D2mit14; D2mgh11 (α 1 Na,K-ATPase); D2mit12; D2mit10; CAMK, and D2mit6 (14)

informative for our Dahl S×Dahl R cross. Nine other markers (D2mgh14, D2mit5, CPB, D2mit17, D2mgh15, D2mit13, D2mit20, D2mgh12, and D2mit5) (14) were

15 also investigated but were found to be non-polymorphic in our cross. Correlation of blood pressure parameters and genotypes for the different chromosome 2 markers was analyzed by one-way ANOVA (SigmaStat; Jandel Scientific, San Rafael, CA). Correction for multiple comparisons was not done, as parameters studied are closely related phenotypes.

20

EXAMPLE 2

Ascertainment of genotype and phenotype of Dahl S and Dahl R strains.

Due to the inadvertent genetic contamination of Dahl S rats at the sole commercial source resulting in subsequent contamination, the first transgenic lines were all terminated. To perform transgenic and cosegregation studies in

non-contaminated Dahl S rats, collaboration was set up with Harlan Sprague Dawley, Inc. (19) to identify non-contaminated Dahl S^{HSD} rats. In 1994, experiments were begun to ascertain non-contaminated genotype and salt-sensitive hypertension phenotype of the Dahl S^{HSD} foundation colony, and, in parallel, the
5 inbred genotype and salt-resistance phenotype of Dahl R^{HSD} rats.

Fig. 1 shows the genetic analysis of Dahl S^{HSD} rats. (A) Genotyping with contamination-indicative markers (20) corroborates non-genetic contamination of Dahl S^{HSD} foundation colony rats. A representative panel is shown for the R80 marker (20) demonstrating non-heterozygosity among Dahl
10 S^{HSD} and Dahl R^{HSD} foundation colony rats; non-heterozygosity was detected in all contamination-indicative (20) markers (see Table I). The respective sizes of amplified product were: Dahl S ≠ Dahl R with R1041, R138, and R80 markers; Dahl S = Dahl R with R721 GCA, R354. (B) PASA detection of T¹⁰⁷⁹/A transversion in Dahl S^{HSD} rat genomic DNA corroborates Q276L α1 Na,K-ATPase
15 mutation. Comparing two Dahl R (R) and two Dahl S (S) rat genomic DNA samples, PASA analysis using primer-specific for T1079 detects significantly

Table I
Genotype Analysis of Dahl S^{HSD} and Dahl R^{HSD} Rat Strains

Rat markers	Results
Informative for genetic contamination of Dahl S ^{HSD} :	No variations in S ^{HSD}
GCA, R80, R138, R1041, R721, R354	No variations in R ^{HSD}
S ≠ R markers:	
D1: mgh6, mgh11, mgh14, mit2, mit13; D2: mit6, mit10, mit11, mit12, mit13, mit14, mit16, mit20, mit21, mgh11, mgh15, camk, UO1224; D3: mgh1, mgh17, mit3, mit13, mit14, D4: mgh15, mit2, mit9, mit10, mit19, mit20; D5: mgh12, mit4, mit7, mit9, mit10, mit11, mit13, D5Rjrl; D6: mgh9, mit2, mit3, mit8, mit9, R721; D7: mgh3, mit3, mit9, mit11, mit12, mit13, mit13; D8: mgh7, mit1, mit6; D9: mit5; D10: mgh4, mgh10, mit2, mit3, mit4; D11: mgh5, mgh6; D12: mgh1, mgh5, mit2, mit5, mit6; D13: mit1, mit3, mit5; D14: mit1, mit7; D17: mgh1, mit1, mit3, mit4; D19: mgh4, mit3; D20: mgh1; DX: mgh4	S ^{HSD} = S ^{Rapp} ≠ R ^{HSD}
D1: cype; D2: mgh14, UO1223; D3: mit6; D4: mit17; D7: mit2; D1: mit5, mit6; D14: mit4; D15: mgh3, mgh5, mit1; D16: mit5; D17: mgh4; DX: mgh5, mit1	S ^{HSD} = S ^{Rapp} = R ^{HSD}
D1: mgh7	S ^{HSD} ≠ S ^{Rapp} = R ^{HSD}
D2: mit5	S ^{HSD} = R ^{HSD} S ^{Rapp} S
S = R markers:	
D2: mit15, mit17, mgh12, cpb; D3mit4, D12mit1; DXmgh1, UO1223	S ^{HSD} = S ^{Rapp} = R ^{HSD}
Markers informative for the contamination of the Dahl S ^{HSD} rats (20) as well as markers reported to be informative for Dahl S and R strains were used (14, 22). Some differences from original report are detected; however, identity with Dahl S ^{Rapp} rat genotype corroborates Dahl S ^{HSD} as non-genetically-contaminated. HSD, rats from Harlan Sprague Dawley, Inc.; S ^{Rapp} , Dahl S rats obtained by HSD from Dr. John Rapp. Marker nomenclature (14, 20, 22).	

more amplified product in Dahl S rat samples (arrow) compared with Dahl R (R) rat genomic DNA samples at 57°C. Background amplified products could be expected as PASA detects a single base difference. As control, a non-specific marker, Cype (14), was used to indicate relative amounts of genomic DNA in the different samples (arrowhead). Taking the ratio of PASA-product to Cype-amplified product, Dahl S samples exhibit ratios > 1 ; whereas Dahl R samples exhibit ratios < 1 . These results indicate the presence of T¹⁰⁷⁹ in Dahl S rat genomic DNA corroborating the Q276L $\alpha 1$ Na,K-ATPase variant as previously described (8, 9).

Using six microsatellite markers informative for the reported genetic contamination (20), foundation colony Dahl S^{HSD} and Dahl R^{HSD} rats were checked; no heterozygosity was detected (Fig. 1 A, Table I). Blood pressure phenotypes of foundation colony Dahl S^{HSD} and Dahl R^{HSD} rats were ascertained using radiotelemetric blood pressure measurements on a high salt (8% NaCl) diet begun at 10 wk of age. Severe salt-sensitive hypertension was detected in male and female Dahl S rats in contrast to salt-resistant normotension in male and female Dahl R rats (Table II). The data parallel the blood pressure phenotypes reported in the original Dahl S/JR and Dahl R/JR characterization (21). Only after this ascertainment were non-contaminated Dahl S^{HSD} and Dahl R^{HSD} rats obtained for transgenic experiments begun in 1995. Random testing of transgenic donor female and male Dahl S rats further corroborated absence of genetic contamination.

Additionally, genotyping analysis using a panel of 97 microsatellite markers informative for Dahl S and Dahl R strains and eight markers identical in Dahl S and R strains (14, 22) was done comparing Dahl S^{HSD} and Dahl R^{HSD} rats used for our experiments, with Dahl S^{Rapp} rats obtained by Harlan Sprague Inc.

from J. Rapp (21). As seen in Table I, 103 of 105 markers were identical between Dahl S^{HSD} and Dahl S^{Rapp} rats; differences were noted at two markers (D1mgh7 and D2mit5); heterozygosity was detected in the Dahl S^{Rapp} rats at D2mit13. These results document the non-genetic contamination of Dahl S^{HSD} and acceptable polymorphic differences between Dahl S^{HSD} and Dahl S^{Rapp} due to separate inbreeding over two decades.

Furthermore, we corroborated once again the presence of Q276L mutation in Dahl S^{HSD} and its absence in Dahl R rat^{HSD} genomic DNA by error-independent PCR allele-specific amplification (PASA) detecting T¹⁰⁷⁹ in Dahl S, in contrast to non-T¹⁰⁷⁹ in Dahl R genomic DNA (Fig. 1 B). This corroborates previous PASA results (9). However, we note that sequencing of a Dahl S α 1 Na,K-ATPase genomic DNA fragment encompassing amino acid 276 isolated from a Fix II Dahl S^{HSD} rat genomic library did not detect the A¹⁰⁷⁹T transversion underlying the Q276L mutation. In light of the consistent PASA results detecting the Q276L variant-specific T¹⁰⁷⁹ genomic DNA and previous observations demonstrating that PCR amplification reproducibly changed the Dahl S variant T¹⁰⁷⁹ to A¹⁰⁷⁹ (9), it becomes apparent that amplification of this genomic DNA region is indeed [T¹⁰⁷⁹- A¹⁰⁷⁹]-specific error prone.

EXAMPLE 3

20 Development of Dahl S transgenic rat lines

Based on observations that male and female F1(Dahl S×Dahl R) rats have blood pressures closer to the Dahl R rat strain after 8 wk of high salt (8% NaCl) diet (Table II), it becomes apparent that SS-EHT in the Dahl S rat model is recessive. Accordingly, a robust transgenic design should involve the transfer of

Table II
Analysis of Blood Pressure Phenotype of Dahl S^{HSD} and Dahl R^{HSD}

Strain	n	SBP	Δ SBP	DBP	DBP	MAP	MAP
Dahl S ♂	6	220±7.1	(S-R) = 90.0	163±7.9	(S-R) = 69.3	153±12.1	(S-R) = 71.8
Dahl R ♂	5	130±1.3		93±1.6		111±1.5	
F1(S×R) ♂	12	152±1.4	(F1-R) = 22.0	110±1.5	(F1-R) = 16.4	130±1.5	(F1-R) = 19.3
Dahl S ♀	6	199±6.9	(S-R) = 75.7	143±4.9	(S-R) = 58.8	161±7.7	(S-R) = 59.0
Dahl R ♀	5	121±3.4		84±1.9		102±2.9	
F1(S×R) ♀	5	138±5.4	(F1-R) = 16.9	98±5.0	(F1-R) = 13.4	117±5.0	(F1-R) = 15.0

Ascertainment of salt sensitivity in the Dahl S rats and salt resistance in Dahl R rats was obtained by non-stress 24-h measurements of blood pressure by radiotelemetry. SBP, systolic; DBP, diastolic blood pressure; MAP, mean arterial pressure in mmHg. Means±SEM are given; Δ BP, increment rise in BP from baseline after 8 wk of high (8% NaCl) diet; (S-R), difference between Dahl S and Dahl R mean BP; (F1-R) difference between F1 mean BP and Dahl R mean BP. For each rat, BP was measured by radiotelemetry and the average obtained of 288 data points (10-s recordings every 5 min) over 24 h in one no-entry day 8 wk after high salt (8% NaCl) challenge was begun at 10 wk.

Dahl R wt Q276 $\alpha 1$ Na,K-ATPase gene into the Dahl S genetic background, testing its effects on salt-sensitive hypertension phenotype.

Fig. 2 shows the molecular characteristics of transgenic Tg[wta1] lines.

(A) The transgene construct, Tg[wta1], is comprised of [1288 bp] of wt $\alpha 1$ Na,K-ATPase 5' flanking regulatory region (wt $\alpha 1$ promoter), linked to wt (Q276) $\alpha 1$ Na,K-ATPase cDNA: spanning the entire 206-bp 5' untranslated region, full length 1,028-amino acid-coding region, and 131 bp of 3' untranslated region; linked to 199 bp of SV40 polyadenylation signal. (B) Southern blot analysis of transgenic F1 hemizygous Dahl S rats representing the three founder lines, Tg[wta1]₃₇ (lane 1); Tg[wta1]₄₈ (lane 2); Tg[wta1]₂₄ (lane 3), control non-transgenic Dahl S rat DNA (lane 4). M, Hind III molecular weight markers from top to bottom: 23,130 bp; 9,416 bp; 6,557 bp; and 4,361 bp. As shown on the left, SacI digested genomic DNA reveals intact Tg[wta1] transgene (4.657-kb fragment at closed arrow) detected only in the transgenic rats (lanes 1-3) and not in the non-transgenic control (lane 4). Other hybridizing SacI DNA fragments (arrowhead) in lane 1, ~ 7 kb; lane 2, ~ 24 kb; and lane 3, ~ 9.5 kb, indicate different random integration sites of the transgene into the genome. Additionally, different copy numbers are evident: Tg[wta1]₄₈ (lane 2) > Tg[wta1]₂₄ (lane 3) > Tg[wta1]₃₇ rat (lane 1). On the right, HindIII restriction digestion reveals the intact transgene (closed arrow) with a > 30-kb fragment in the transgenic rat lines, absent in control (lane 4). The endogenous $\alpha 1$ Na,K-ATPase HindIII fragment is smaller, ~ 30 kb (open arrow), and is detected in transgenic and control non-transgenic rat genomic DNA. (C) The composition of the RPA probe used to assess wt (transgene) and Q276L variant (endogenous) $\alpha 1$ Na,K-ATPase RNA levels is presented: a 310-nt RPA probe comprised of 131 bp of 3' untranslated (UT) region of the $\alpha 1$ Na,K-ATPase cDNA present in both transgene and

endogenous $\alpha 1$ Na,K-ATPase, linked to 109 bp of SV40 sequence, which is present only in the transgene; and 70-bp vector sequence. The transgene wt $\alpha 1$ Na,K-ATPase RNA is expected to be 240-nt-long, distinguished from the endogenous Q276L variant $\alpha 1$ Na,K-ATPase RNA, expected to be 131-nt long.

5 (D) RPA of total cellular RNA from heart (lanes 1 and 2), brain (lanes 3 and 4), and kidney (lanes 5 and 6) of homozygous transgenic Tg[wt $\alpha 1$] (lanes 2, 4, and 6) and control non-transgenic (lanes 1, 3, and 5) Dahl S rats. (-), control yeast RNA; 32 P, RPA radiolabeled probe; m, molecular size markers in base pairs from top to bottom: pBR322 DNA-MspI digest: 404, 307, 242, 238, 217, 201, 190, 180, 160,
10 147, 123, 110 bp. (E) RPA of total aortic RNA from homozygous transgenic (lanes 4 and 5) and age-matched control (lanes 1, 2, and 3) non-transgenic Dahl S rats. (F) Longer exposure (10 \times) of E. (closed arrow), 240-nt protected fragment indicative of wt transgene $\alpha 1$ Na,K-ATPase mRNA; (open arrow), partial protection 131-nt fragment, indicative of endogenous Q276L variant $\alpha 1$
15 Na,K-ATPase mRNA. (G) Assessment of wt (transgene) and Q276L variant (endogenous) $\alpha 1$ Na,K-ATPase RNA levels in membrane-bound polysomes of homozygous Tg[wt $\alpha 1$] rats. The identical RPA probe (shown in C) was used to perform RNase protection assays (RPA) on membrane-bound polysomal RNA isolated from homozygous Tg[wt $\alpha 1$]24 Dahl S rat kidney (lane 1). 32 P, RPA
20 probe; m, molecular size markers in base pairs from top to bottom: pBR322 DNA-MspI digest: 404, 307, 242, 238, 217, 201, 190, 180, 160, 147 bp. Top (arrowhead), 240-nt protected fragment indicative of wt transgene $\alpha 1$ Na,K-ATPase mRNA; bottom (arrowhead), partial protection 131-nt fragment, indicative of endogenous Q276L variant $\alpha 1$ Na,K-ATPase mRNA.

25 To attain appropriate spatial and developmental gene regulation, the transgene design links the cognate wt $\alpha 1$ Na,K-ATPase promoter region,

functionally validated previously (15); the Dahl R wt $\alpha 1$ Na,K-ATPase cDNA (8, 9); and SV40 polyadenylation signal sequences, Tg[wt $\alpha 1$] (Fig. 2 A). Transgenic rats were developed as described (16). Three transgenic lines were developed, Tg[wt $\alpha 1$]₂₄, ₃₇, and ₄₈. Southern blot analyses revealed intact transgene sequences in all three transgenic lines showing the predicted 2.199-kb NcoI fragment, the predicted 4.657-kb SacI fragment (Fig. 2 B), and HindIII restriction digestion fragments greater than the microinjected 5.376-kb transgene recombinant construct hybridizing to the $\alpha 1$ Na,K-ATPase cDNA probe (Fig. 2 B). Different copy numbers are also noted. Other restriction fragments hybridizing to the $\alpha 1$ Na,K-ATPase cDNA probe are detected in both control and transgenic rat DNAs representing the endogenous $\alpha 1$ Na,K-ATPase gene (Fig. 2 B).

To gain insight into the relative ratio of expression of the endogenous Q276L variant versus the transgene wt $\alpha 1$ Na,K-ATPase, RPAs were done (Fig. 2, C-F). The endogenous Q276L $\alpha 1$ Na,K-ATPase variant is detected as the expected 131-nt-long partial protection fragment (Fig. 2 C) in both control (odd numbered) and transgenic (even numbered) rat RNA samples (Fig. 2 D): heart (lanes 1 and 2), brain (3 and 4), and kidney (5 and 6). The endogenous-specific 131-nt-long fragment is likewise detected in aorta on short (Fig. 2 E) and longer exposure (Fig. 2 F). The relative levels detected are consistent with spatial expression patterns in the rat (6). In contrast, the transgene-specific $\alpha 1$ Na,K-ATPase expected 240-nt protected fragment (Fig. 2 C) is detected only in transgenic rat tissue RNA samples as shown in Fig. 2 D: lane 2, heart; lane 4, brain; lane 6, kidney; and Fig. 2 E, lanes 4 and 5, Fig. 2 F, lanes 4 and 5, aorta. It should be noted that the total amount of $\alpha 1$ Na,K-ATPase transcript is not dramatically increased by the level of transgene expression in both transgenic lines with Tg[wt $\alpha 1$]₂₄ exhibiting higher expression levels compared with Tg[wt $\alpha 1$]₄₈.

transgenic line.

To determine the membrane-integrated relative protein levels of transgene-to-endogenous $\alpha 1$ Na,K-ATPases in the absence of an informative antibody, assessment of their respective relative levels was determined in the renal translational pool compartmentalized to kidney membrane-bound polysomes of homozygous transgenic Tg[wt $\alpha 1$] Dahl S rats. This was done by RPA analysis of membrane-bound polysomal RNA isolated from a homozygous transgenic Tg[wt $\alpha 1$] Dahl S rat kidney using the same probe depicted in Fig. 2 C. As shown in Fig. 2 G, the 240-nt protected fragment representing the transgene wt $\alpha 1$ Na,K-ATPase transcript is almost equivalent in amount to the 131-nt-long protected fragment representing the endogenous Q276L variant $\alpha 1$ Na,K-ATPase transcript (~ 40:60 ratio of transgene wt $\alpha 1$ Na,K-ATPase to endogenous Q276L variant $\alpha 1$ Na,K-ATPase). This is in marked contrast to the underrepresentation of the transgene wt RNA in the total cellular pool (Fig. 2 D). Although the precise mechanism that could account for this differential representation, is as yet unclear, it is likely that structural differences within the 3'UT between the wt (transgene) and Q276L variant (endogenous) mRNAs could account in part for their differential RNA stability when compartmentalized to the non-translational pool.

EXAMPLE 4

20 Alleviation of salt-sensitive hypertension phenotype.

To test whether Tg[wt $\alpha 1$] transgene expression modifies the salt-sensitive hypertension phenotype of inbred Dahl S rats, we analyzed three parameters: (a) life span on a high salt (8% NaCl) and on regular (0.4% NaCl) rat chow, (b) blood pressure levels, and (c) hypertensive renal disease. *A priori*, concordance of effects in all three parameters would strongly indicate a bona fide

mechanistic role for $\alpha 1$ Na,K-ATPase. Life span was analyzed in hemizygous transgenic rats challenged with a high salt (8% NaCl) diet at six wk of age.

Fig. 3 shows the life span in hemizygous and homozygous transgenic Tg[wt $\alpha 1$] Dahl S rats compared with control non-transgenic Dahl S rats. (A)

- 5 Hemizygous male and female transgenic rats from the three Tg[wt $\alpha 1$] lines on high salt (8% NaCl) diet begun at 6 wk of age lived longer (13.0 ± 0.5 wk; $n = 23$) than control littermate non-transgenic (11.4 ± 0.4 wk; $n = 19$) Dahl S rats ($P < 0.01$, one-way ANOVA). (B) Homozygous male and female Tg[wt $\alpha 1$]₂₄ and Tg[wt $\alpha 1$]₄₈ rats on regular (0.4% NaCl) rat diets lived longer (54.8 ± 2.3 wk; $n = 10$), compared
10 with non-transgenic control Dahl S rats (31.2 ± 1.2 wk; $n = 19$); $P < 10^{-9}$, one-way ANOVA.

- As seen in Fig. 3 A, hemizygous male and female rats from three transgenic lines lived longer than littermate non-transgenic Dahl S rat controls. Mean life span of hemizygous Tg[wt $\alpha 1$] rats (13.0 ± 0.5 wk, $n = 23$) increased
15 14% compared with controls (11.4 ± 0.4 wk, $n = 19$), $P < 0.01$ one-way ANOVA. Upon successfully breeding Tg[wt $\alpha 1$]₂₄ and Tg[wt $\alpha 1$]₄₈ lines to homozygosity, life span was analyzed on a regular (0.4% NaCl) rat chow. As seen in Fig. 3 B, male and female homozygous rats lived longer than control non-transgenic Dahl S rats. Mean life span of homozygous Tg[wt $\alpha 1$]_{24,48} rats (54.8 ± 2.3 wk, $n = 10$) increased
20 75.6% compared with controls (31.2 ± 1.2 wk, $n = 19$), $P < 10^{-9}$ by one-way ANOVA. Improvement in mortality suggested that salt-sensitive hypertension phenotype was most likely alleviated in the different transgenic rat lines.

- Blood pressure measurements were then analyzed comparing homozygous male and female transgenic Tg[wt $\alpha 1$]₂₄ rats with non-transgenic
25 age-matched Dahl S control rats. As seen in Table III, group means of 24-h SBP, DBP, and MAP levels in both male and female transgenic Tg[wt $\alpha 1$]₂₄ rats were

consistently lower than blood pressure levels detected in age-matched control non-transgenic Dahl S rats. Likewise, the levels of increment rise in blood pressure parameters, SBP, DBP, and MAP, after 4 wk of high salt challenge were also significantly lower in both male and female transgenic Tg[wt α 1]₂₄ rats (Table
5 III).

To assess potential improvement in EHT-induced target organ damage, comparison of PAS-stained renal sections from five transgenic rat kidneys representing homozygous transgenic Tg[wt α 1]₂₄ and Tg[wt α 1]₄₈ rats and from four control non-transgenic rat kidneys was done. Low magnification revealed
10 significant differences between transgenic rat kidney sections and control non-transgenic rat kidney sections. No differences were noted between sexes.

Fig. 4 shows the comparative analysis of degree of hypertensive renal disease. Representative PAS-stained renal sections of non-transgenic Dahl S rat kidney (A) show more severe renal pathology after 4 wk of high salt diet
15 compared with age-matched transgenic Dahl S rat kidney (B). Low power magnification reveals more hyaline casts and abnormal glomeruli with intensely PAS-positive mesangial thickening and glomerulosclerosis per unit area in non-transgenic rat kidney section (A) compared with transgenic rat kidney section (B). Abnormal glomeruli with grade IV Raij pathology score lesions are marked
20 (arrowhead). C, D, E, F, and G show high power magnification demonstrating different grades of glomerular pathology used as parameters for quantitation of extent of renal pathology based on the Raij pathology score (18). (C) normal glomerulus; (D)

Table III
Comparison of Blood Pressure of Transgenic and Non-transgenic Dahl S Rats

BP Parameter (mmHg)	Control ♂ (n = 5)	Tg[wta1] ₂₄ ♂ (n = 6)	Control ♀ (n = 4)	Tg[wta1] ₂₄ ♀ (n = 6)
SBP±SEM	231.4±6.0	190.3±5.4**	220.3±3.6	186.8±5.7†
DBP±SEM	179.2±5.0	141.8±4.7**	169.8±4.2	137.2±6.2†
MAP±SEM	203.6±5.2	165.2±5.0**	192.3±3.4	163.0±5.5†
ΔSBP±SEM	82.6±4.2	47.8±8.8*	66.8±2.4	41.2±4.9*
ΔDBP±SEM	68.6±3.2	38.2±5.2**	52.5±3.7	31.2±4.2*
ΔMAP±SEM	75.4±3.5	43.5±7.1*	58.0±4.3	36.7±4.6*

Blood pressure of homozygous transgenic Tg[wta1]₂₄ rats were compared with age- and sex-matched non-transgenic Dahl S rats after 4 wk of high (8% NaCl) salt diet begun at 12 wk of age. BP parameters analyzed: systolic (SBP), diastolic (DBP), mean arterial pressure (MAP), as well as increment rise (Δ) in respective BP parameters after 4 wk of high salt (8% NaCl) challenge (Methods). Data were analyzed using non-parametric one-way ANOVA and one-way ANOVA on ranks. Correction for multiple comparisons was not done since the multiple phenotypes studied (SBP, DBP, MAP, ΔSBP, ΔDBP, ΔMAP) are correlated to a high degree. For each rat, BP was measured by radiotelemetry and the average obtained of 288 data points (10-s recordings every 5 min) over 24 h in one no-entry day 4 wk after high salt (8% NaCl) challenge was begun at 12 wk of age. BP parameters per rat in mmHg, millimeters mercury; n, number of rats in group; SEM, standard error of the mean; (

†), $P < 0.05$; (

*) $P < 0.01$; (

**), $P < 0.001$.

grade I glomerular pathology with mesangial thickening and/or glomerulosclerosis covering 25% of glomerulus; (E) grade II glomerular pathology involving 50% of glomerulus; (F) grade III glomerular pathology involving 75% of glomerulus; (G) grade IV glomerular pathology, 100% involvement. Calculation of the total pathology score = [1(% grade I) + 2(% grade II) + 3(% grade III) + 4(% grade IV)] indicates worse renal pathology with increasing scores.

As shown in Fig. 4, a greater number of magenta PAS-positive abnormal glomeruli are seen in a representative control rat kidney section (Fig. 4 A) compared with a representative transgenic kidney section (Fig. 4 B), indicating less hypertensive renal disease in transgenic rats. This was corroborated by quantitative analysis of renal pathology based on the scoring system described by Raij et al. (18), wherein glomeruli are graded for degree of mesangial thickening and glomerulosclerosis. As shown in Fig. 4, a glomerulus with 25% mesangial thickening and/or glomerulosclerosis is grade I (Fig. 4 D); grade II is 50% pathologic involvement (Fig. 4 E); grade III, 75% involvement (Fig. 4 F); and grade IV, 100% pathologic involvement (Fig. 4 G), in contrast to a normal glomerulus (Fig. 4 C). A total pathology score is calculated with worse severity correlated with higher pathology scores (18). Analysis of renal sections from four control non-transgenic rats (628 total glomeruli scored) compared with five transgenic rat kidney sections (1,213 total glomeruli scored) for severity of mesangial thickening and glomerulosclerosis revealed a 52% decrease in Raij renal pathology score in transgenic rat kidneys compared with control rat kidneys, $P = 0.0025$ (non-parametric ANOVA) Table IV.

This decrease in renal pathology in transgenic Tg[wt α 1] Dahl S rats is consistent with the observed improvement in life span and the alleviation of

Table IV
Quantitative Analysis of Renal Pathology

Group (n)	% Normal \pm SEM	% Gr. I \pm SEM	% Gr. II \pm SEM	% Gr. III \pm SEM	% Gr. IV \pm SEM	Pathology score \pm SEM
Control (4)	20.1 \pm 5.2	31.7 \pm 5.6	16.3 \pm 4.4	13.5 \pm 2.2	18.3 \pm 4.3	178.2 \pm 15.0
Transgenic (5)	41.7 \pm 4.5	38.8 \pm 1.8	12.4 \pm 2.8	6.0 \pm 1.2	1.1 \pm 0.5	85.8 \pm 9.9
Probability	0.0170	NS	NS	0.0070	0.0016	0.0025

Quantitative analysis of renal pathology (13) comparing transgenic Dahl S rats ($n = 5$) and control non-transgenic rats ($n = 4$). PAS-stained renal sections were graded in a blind manner for mesangial thickening and glomerulosclerosis; total of 628 glomeruli for control non-transgenic rats; 1,213 glomeruli for transgenic rats. Scoring of pathology was done as described (Fig. 4). Data were analyzed using non-parametric ANOVA; NS, not significant; SEM, standard error of the mean; n , number of rats represented in the analysis.

SS-EHT. More importantly, the concordance of improvement in three measures, life span, blood pressure, and hypertensive renal disease, as well as the 40:60 transgene: endogenous $\alpha 1$ Na,K-ATPase ratio provide evidence to meet our third criteria for the role of the $\alpha 1$ Na,K-ATPase gene in SS-EHT.

5

EXAMPLE 4

Intercross linkage analysis.

To fulfill criterion 4, cosegregation analysis was done on fifty F₂(S×R) hybrid male rats phenotyped for SBP, DBP, MAP, heart rate, and activity by radiotelemetry at baseline (10 wk of age) and after 8 wk of high (8% NaCl) salt challenge. These 50 F₂ rats were genotyped at 15 markers that spanned chromosome 2 (14). ANOVAs comparing phenotypes across the three genotypic categories for each informative marker locus (6 out of 15) were carried out.

Fig. 5 shows cosegregation analysis of the $\alpha 1$ Na,K-ATPase locus with salt-sensitive hypertension. Total chromosome 2 scan analyzing marker cosegregation with salt-sensitive hypertension in an F₂(Dahl S× Dahl R) cohort (n = 50 males) measured as increment rise in 24-h average systolic (SBP), diastolic (DBP) and mean arterial pressures (MAP) obtained after 8 wk of high (8% NaCl) salt diet. Markers informative for the Dahl S and R hybrid cross are marked along their respective relative location on chromosome 2 in centimorgans (cM) based on the rat map (14). Greatest significance is seen with the $\alpha 1$ Na,K-ATPase locus (D2mgh11 marker) and the D2mit14 marker, < 2.2 cM away. In contrast to other studies (22), D2mit12 and CAMK markers do not cosegregate with salt-sensitive hypertension. Correlation trends along chromosome 2 are parallel for SBP, DBP, and MAP.

Table V
Correlation of Chromosome 2 Genotype and Blood Pressure

Locus	BP	Genotype			Δ	(SS-RR) P value
		RR	RS	SS		
D2mit6	Δ DBP	22.9 \pm 2.84	16.6 \pm 1.43	22.7 \pm 2.39	-0.2	0.9542
	Δ SBP	28.7 \pm 3.84	23.6 \pm 1.75	31.3 \pm 3.28	2.6	0.3943
	Δ MAP	26.0 \pm 3.37	20.1 \pm 1.63	27.1 \pm 2.80	1.1	0.4628
	(n)	(14)	(26)	(10)		
D2Mit10	Δ DBP	16.3 \pm 2.27	19.4 \pm 1.87	22.9 \pm 2.16	6.6	0.0439
	Δ SBP	22.0 \pm 2.72	26.4 \pm 2.46	31.0 \pm 2.57	9.0	0.0188
	Δ MAP	19.3 \pm 2.47	23.0 \pm 2.23	27.1 \pm 2.34	7.8	0.0305
	(n)	(12)	(25)	(13)		
D2Mit12	Δ DBP	16.9 \pm 2.27	19.2 \pm 2.16	22.3 \pm 1.84	5.4	0.0695
	Δ SBP	23.0 \pm 2.72	25.7 \pm 2.80	30.6 \pm 2.30	7.6	0.0401
	Δ MAP	20.0 \pm 2.47	22.4 \pm 2.55	26.6 \pm 2.04	6.6	0.0466
	(n)	(13)	(21)	(16)		
D2Mgh11 (α 1)	DBP	15.5 \pm 1.78	19.0 \pm 2.09	23.2 \pm 1.88	7.7	0.00920
	Δ SBP	21.1 \pm 2.07	25.2 \pm 2.59	32.3 \pm 2.39	11.2	0.00263
	Δ MAP	18.4 \pm 1.84	22.1 \pm 2.40	27.9 \pm 2.13	9.5	0.00376
	(n)	(11)	(23)	(16)		
D2Mit14	Δ DBP	15.6 \pm 1.78	19.0 \pm 2.08	23.2 \pm 1.88	7.6	0.00920
	Δ SBP	21.1 \pm 2.08	25.2 \pm 2.58	32.3 \pm 2.40	11.2	0.00263
	Δ MAP	18.4 \pm 1.84	22.1 \pm 2.40	27.9 \pm 2.13	9.5	0.00376
	(n)	(11)	(23)	(16)		
CAMK	Δ DBP	16.8 \pm 1.88	20.4 \pm 2.21	29.3 \pm 2.04	3.5	0.2488
	Δ SBP	21.5 \pm 2.07	27.1 \pm 2.74	29.0 \pm 2.64	7.5	0.0548
	Δ MAP	19.2 \pm 1.88	23.9 \pm 2.50	24.7 \pm 2.42	5.5	0.1223
	(n)	(11)	(21)	(18)		

Cosegregation of increment rise in diastolic, systolic, and mean arterial pressure by genotype for different loci on rat chromosome 2 in F2(S α 1 \times R α 1) male rats fed a high salt diet for 8 wk. Peak correlation is noted at the α 1 locus (D2mgh11) and at the locus marked by D2 mit14 marker, < 2.2 cM away (14). SS, homozygous for Dahl S allele; RR, homozygous for Dahl R allele; SR, heterozygous; P value, probability based on one-way analysis of variance of difference in Δ BP between SS and RR genotypes; (Δ BP), increment rise in BP after 8 wk of high salt diet from baseline BP; SEM, standard error of the mean; DBP, diastolic blood pressure; SBP, systolic blood pressure; MAP, mean arterial pressure in mm.Hg; n, number of rats. Correction for multiple comparisons was not done as parameters studied are closely related phenotypes.

As seen in Table V and Fig. 5, the most significant ANOVA results were detected at the $\alpha 1$ Na,K-ATPase locus (D2mgh11) and at the D2mit14 marker, 2.2 centimorgans (cM) away, for SBP ($P = 0.00268$), DBP ($P = 0.00920$), MAP ($P = 0.00376$). The fact that all three blood pressure measures provide similar results is in contrast to other F2 cosegregation studies that have detected cosegregation with one blood pressure parameter but not with the others, e.g., locus cosegregation with DBP and pulse pressure, but not with SBP or MAP (23). These results indicate that the $\alpha 1$ Na,K-ATPase locus meets criterion 4.

References

1. Herrera, V.L.M., and N. Ruiz-Opazo (1991) Genetics of hypertension: a multidisciplinary challenge. *Trends Cardiovasc. Med* 1: 185-189.
2. Herrera, V.L.M., and N. Ruiz-Opazo (1994) Beyond genetic markers: hypertension genes. *J. Hypertension*. 12: 847-856.
3. Dahl, L.K, M. Heine, and L. Tassinari (1972) Role of genetic factors in susceptibility to experimental hypertension due to chronic excess salt ingestion. *Nature*. 194: 480-482.
4. Dahl, L.K., M. Heine, and K. Thompson (1974) Genetic influence of the kidneys on blood pressure: evidence from chronic renal homografts in rats with opposite predispositions to hypertension. *Circ. Res* 34: 94-101.
5. Vander, A.J. 1991. *Renal Physiology*. 4th edition. McGraw-Hill, Inc. New York. 83-111.
6. Herrera, V.L.M., T. Cova, D. Sassoon, and N. Ruiz-Opazo (1994) Developmental cell-specific regulation of 1, 2, and 3 Na,K-ATPase gene expression. *Am. J. Physiol* 266: C1301-C1312.
7. DeWardener, H.E. (1990) The primary role of the kidney and salt intake in

the aetiology of essential hypertension, part II. Clin. Sci 79: 289-297.

8. Herrera, V.L.M., and N. Ruiz-Opazo (1990) Alteration of 1 Na,K-ATPase 86R+ influx by a single amino acid substitution. Science. 249: 1023-1026.

9. Ruiz-Opazo, N., F. Barany, K. Hirayama, and V.L.M. Herrera (1994)

5 Confirmation of mutant 1 Na,K-ATPase gene and transcript in Dahl salt-sensitive/JR rats. Hypertension. 24: 260-270.

10. Simonet, L., E. St. Lezin, and T.W. Kurtz (1991) Sequence analysis of the 1 Na,K-ATPase gene in the Dahl salt-sensitive rat. Hypertension. 18: 689-693.

10 11. Schull, G.E., J. Greeb, and J.B. Lingrel (1989) Molecular cloning of three distinct forms of the Na,K-ATPase -subunit from rat brain. Biochemistry. 25: 8125-8132.

12. Canessa, M., J.R. Romero, N. Ruiz-Opazo, and V.L.M. Herrera (1993) The 1 Na,K pump of the Dahl salt-sensitive rat exhibits altered Na⁺ modulation of K⁺ transport in red blood cells. J. Membr. Biol 134: 107-122.

15 13. Orosz, D.E., and U. Hopfer (1996) Pathophysiologic consequences of changes in the coupling ratio of Na,K-ATPase for renal sodium reabsorption and its implications for hypertension. Hypertension. 27: 219-227.

14. Jacob, H.J., Brown, D.M. Bunker, R.K. Daly, M.J. Dzau, V.J. Goodman, A. Koike, G. Kren, V. Kurtz, T. Lernmark, et al (1995) A genetic linkage map of the 20 laboratory rat, Rattus norvegicus. Nat. Genet. 9: 63-69.

15. Ruiz-Opazo, N., J.F. Cloix, M.G. Melis, X.H. Xiang, and V.L.M. Herrera (1997) Characterization of a sodium-response transcriptional mechanism. Hypertension. 30: 191-198.

16. Ruiz-Opazo, N., X.H. Xiang, and V.L.M. Herrera (1997) Pressure-overload 25 deinduction of human 2 Na,K-ATPase gene expression in transgenic rats. Hypertension. 29: 606-612.

17. Dallner, G. 1974. Isolation of rough and smooth microsomes - general. In Methods in Enzymology, Vol. XXXI, S. Fleischer and L. Packer, editors. Academic Press, New York. 191-201.
18. Raij, L., S. Azar, and W.K. Keane (1984) Mesangial immune injury,
5 hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 26:
137-143.
19. Herrera, V.L.M., R.J. Russell, Q. Fang, J.R. McGinley, and N. Ruiz-Opazo
(1995) Genotypic and phenotypic characterization of inbred Dahl salt-sensitive
(SS/JR Hsd) and salt-resistant (SR/JRHsd) rats. Contemp. Top. 34: 51
- 10 20. Lewis, J.L., R.J. Russell, and D.G. Warnock (1994) Analysis of the genetic
contamination of salt-sensitive Dahl/Rapp rats. Hypertension. 24: 255-259.
21. Rapp, J.P., and H. Dene (1985) Development and characteristics of inbred
strains of Dahl salt-sensitive and salt-resistant rats. Hypertension. 7: 340-349.
22. Deng, A.Y., H. Dene, and J.P. Rapp (1994) Mapping of a quantitative trait
15 locus for blood pressure on rat chromosome 2. J. Clin. Invest 94: 431-436.
23. Dubay, C., M. Vincent, N.J. Samani, P. Hilbert, M.A. Kaiser, J.P. Bérési,
Y. Kotelevtsev, J.S. Beckmann, F. Soubrier, J. Sassard, and G.M. Lathrop (1993)
Genetic determinants of diastolic and pulse pressure map to different loci in Lyon
hypertensive rats. Nat. Genet. 3: 354-357.
- 20 24. St. Lezin, E.M., M. Pravenec, A. Wong, J.-M. Wang, T. Merriouns, S.
Newton, D.E. Stec, R.J. Roman, D. Lau, R.C. Morris, and T.W. Kurtz (1994)
Genetic contamination of Dahl SS/JR rats: impact on studies of salt-sensitive
hypertension. Hypertension. 23: 786-790.
- 25 25. Clark, J.S., B. Jeffs, A.O. Davidson, W.K. Lee, N.H. Anderson, M.T.
Bihoreau, M.J. Brosnan, A.M. Devlin, A.W. Kelman, K. Lindpaintner, and A.F.
Dominiczak (1996) Quantitative trait loci in genetically hypertensive rats.

Hypertension. 28: 898-906.

26. Samani, N.J., D. Gauguier, M. Vincent, M.A. Kaiser, M.T. Bihoreau, D. Lodwick, R. Wallis, V. Parent, P. Kimber, F. Rattray, et al (1996) Analysis of quantitative trait loci for blood pressure on rat chromosomes 2 and 13.

5 Hypertension. 28: 1118-1122.

27. Lander, E., and L. Kruglyak (1995) Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat. Genet. 11: 241-247.

28. National Heart, Lung and Blood Institute Report of the Task Force on Research in Hypertension. United States Department of Health and Human

10 Services. May 1991.

29. Goldman, D. (1996) High anxiety. Science. 274: 1483.

30. Lesch, K.P., D. Bengel, A. Heils, S.Z. Sabol, B.D. Greenberg, S. Petri, J. Benjamin, C.R. Muller, D.H. Hamer, and D.L. Murphy (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene

15 regulatory region. Science. 274: 1527-1531.

31. Lander, E., and N.J. Schork (1994) Genetic dissection of complex traits. Science. 265: 2037-2048.

Other Embodiments

20 All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each independent publication or patent application was specifically and individually indicated to be incorporated by reference.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further
25 modifications and this application is intended to cover any variations, uses, or

adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure come within known or customary practice within the art to which the invention pertains and may be applied to the essential features hereinbefore set forth, and follows in the scope of

5 the appended claims.

What is claimed is: